Relevant bibliographies by topics / Nasal dry powder inhaler

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Nasal dry powder inhaler'

Author: Grafiati
Published: 4 June 2021
Last updated: 13 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Nasal dry powder inhaler.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Nasal dry powder inhaler"

1

Farkas, Dale, Michael Hindle, Serena Bonasera, Karl Bass, and Worth Longest. "Development of an Inline Dry Powder Inhaler for Oral or Trans-Nasal Aerosol Administration to Children." Journal of Aerosol Medicine and Pulmonary Drug Delivery 33, no. 2 (April 1, 2020): 83–98. http://dx.doi.org/10.1089/jamp.2019.1540.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Farkas, Dale, Michael Hindle, and P. Worth Longest. "Application of an inline dry powder inhaler to deliver high dose pharmaceutical aerosols during low flow nasal cannula therapy." International Journal of Pharmaceutics 546, no. 1-2 (July 2018): 1–9. http://dx.doi.org/10.1016/j.ijpharm.2018.05.011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lokshina, Е. Е., and О. V. Zaytseva. "Inhalation therapy in children: new opportunities." Russian Pulmonology 29, no. 4 (October 24, 2019): 499–507. http://dx.doi.org/10.18093/0869-0189-2019-29-4-499-507.

Full text
Abstract:
Inhalation therapy is widely used for treatment of acute respiratory infections and asthma in children, and provides more rapid drug delivery in the airways. Treatment success in children with respiratory diseases is defined not only by an adequate choice of the drug and the dosage regimen, but also by inhalation drug delivery system. The choice of drug delivery device in children depends on the child's age and ability to carry out instructions related to the inhalation technique. Incorrect inhalation technique is associated with inappropriate distribution of the drug in the respiratory tract and an unreasonable increase in the volume of therapy, risk of adverse effects, and the total cost of the treatment. Currently, a great number of various drug delivery systems are commercially available, such as a pressurised metered dose inhaler (MDI), a MDI with spacer and facemask, a dry powder inhaler, and a nebulizer. The most optimal inhalation drug delivery device for children is a nebulizer. In this article, the authors discussed benefits and limitations of various drug delivery systems and modern nebulizers used for treatment of the upper and the lower airways including DuoBaby nebulizer 2-in-1 with a nasal aspirator.
APA, Harvard, Vancouver, ISO, and other styles
4

Walther, Frans J., Monik Gupta, Michael M. Lipp, Holly Chan, John Krzewick, Larry M. Gordon, and Alan J. Waring. "Aerosol delivery of dry powder synthetic lung surfactant to surfactant-deficient rabbits and preterm lambs on non-invasive respiratory support." Gates Open Research 3 (January 14, 2019): 6. http://dx.doi.org/10.12688/gatesopenres.12899.1.

Full text
Abstract:
Background: The development of synthetic lung surfactant for preterm infants has focused on peptide analogues of native surfactant proteins B and C (SP-B and SP-C). Non-invasive respiratory support with nasal continuous positive airway pressure (nCPAP) may benefit from synthetic surfactant for aerosol delivery. Methods: A total of three dry powder (DP) surfactants, consisting of phospholipids and the SP-B analogue Super Mini-B (SMB), and one negative control DP surfactant without SMB, were produced with the Acorda Therapeutics ARCUS® Pulmonary Dry Powder Technology. Structure of the DP surfactants was compared with FTIR spectroscopy, in vitro surface activity with captive bubble surfactometry, and in vivo activity in surfactant-deficient adult rabbits and preterm lambs. In the animal experiments, intratracheal (IT) aerosol delivery was compared with surfactant aerosolization during nCPAP support. Surfactant dosage was 100 mg/kg of lipids and aerosolization was performed using a low flow inhaler. Results: FTIR spectra of the three DP surfactants each showed secondary structures compatible with peptide folding as an α-helix hairpin, similar to that previously noted for surface-active SMB in other lipids. The DP surfactants with SMB demonstrated in vitro surface activity <1 mN/m. Oxygenation and lung function increased quickly after IT aerosolization of DP surfactant in both surfactant-deficient rabbits and preterm lambs, similar to improvements seen with clinical surfactant. The response to nCPAP aerosol delivery of DP surfactant was about 50% of IT aerosol delivery, but could be boosted with a second dose in the preterm lambs. Conclusions: Aerosol delivery of active DP synthetic surfactant during non-invasive respiratory support with nCPAP significantly improved oxygenation and lung function in surfactant-deficient animals and this response could be enhanced by giving a second dose. Aerosol delivery of DP synthetic lung surfactant has potential for clinical applications.
APA, Harvard, Vancouver, ISO, and other styles
5

Walther, Frans J., Monik Gupta, Michael M. Lipp, Holly Chan, John Krzewick, Larry M. Gordon, and Alan J. Waring. "Aerosol delivery of dry powder synthetic lung surfactant to surfactant-deficient rabbits and preterm lambs on non-invasive respiratory support." Gates Open Research 3 (March 14, 2019): 6. http://dx.doi.org/10.12688/gatesopenres.12899.2.

Full text
Abstract:
Background: The development of synthetic lung surfactant for preterm infants has focused on peptide analogues of native surfactant proteins B and C (SP-B and SP-C). Non-invasive respiratory support with nasal continuous positive airway pressure (nCPAP) may benefit from synthetic surfactant for aerosol delivery. Methods: A total of three dry powder (DP) surfactants, consisting of phospholipids and the SP-B analogue Super Mini-B (SMB), and one negative control DP surfactant without SMB, were produced with the Acorda Therapeutics ARCUS® Pulmonary Dry Powder Technology. Structure of the DP surfactants was compared with FTIR spectroscopy, in vitro surface activity with captive bubble surfactometry, and in vivo activity in surfactant-deficient adult rabbits and preterm lambs. In the animal experiments, intratracheal (IT) aerosol delivery was compared with surfactant aerosolization during nCPAP support. Surfactant dosage was 100 mg/kg of lipids and aerosolization was performed using a low flow inhaler. Results: FTIR spectra of the three DP surfactants each showed secondary structures compatible with peptide folding as an α-helix hairpin, similar to that previously noted for surface-active SMB in other lipids. The DP surfactants with SMB demonstrated in vitro surface activity <1 mN/m. Oxygenation and lung function increased quickly after IT aerosolization of DP surfactant in both surfactant-deficient rabbits and preterm lambs, similar to improvements seen with clinical surfactant. The response to nCPAP aerosol delivery of DP surfactant was about 50% of IT aerosol delivery, but could be boosted with a second dose in the preterm lambs. Conclusions: Aerosol delivery of DP synthetic surfactant during non-invasive respiratory support with nCPAP significantly improved oxygenation and lung function in surfactant-deficient animals and this response could be enhanced by giving a second dose. Aerosol delivery of DP synthetic lung surfactant has potential for clinical applications.
APA, Harvard, Vancouver, ISO, and other styles
6

Brunaugh, Ashlee D., Hyojong Seo, Zachary Warnken, Li Ding, Sang Heui Seo, and Hugh D. C. Smyth. "Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae." PLOS ONE 16, no. 2 (February 11, 2021): e0246803. http://dx.doi.org/10.1371/journal.pone.0246803.

Full text
Abstract:
Niclosamide (NIC) has demonstrated promising in vitro antiviral efficacy against SARS-CoV-2, the causative agent of the COVID-19 pandemic. Though NIC is already FDA-approved, administration of the currently available oral formulation results in systemic drug levels that are too low for the inhibition of SARS-CoV-2. We hypothesized that the co-formulation of NIC with an endogenous protein, human lysozyme (hLYS), could enable the direct aerosol delivery of the drug to the respiratory tract as an alternative to oral delivery, thereby effectively treating COVID-19 by targeting the primary site of SARS-CoV-2 acquisition and spread. To test this hypothesis, we engineered and optimized composite particles containing NIC and hLYS suitable for delivery to the upper and lower airways via dry powder inhaler, nebulizer, and nasal spray. The novel formulation demonstrates potent in vitro and in vivo activity against two coronavirus strains, MERS-CoV and SARS-CoV-2, and may offer protection against methicillin-resistance staphylococcus aureus pneumonia and inflammatory lung damage occurring secondary to SARS-CoV-2 infections. The suitability of the formulation for all stages of the disease and low-cost development approach will ensure rapid clinical development and wide-spread utilization.
APA, Harvard, Vancouver, ISO, and other styles
7

Alabsi, Wafaa, Fahad A. Al-Obeidi, Robin Polt, and Heidi M. Mansour. "Organic Solution Advanced Spray-Dried Microparticulate/Nanoparticulate Dry Powders of Lactomorphin for Respiratory Delivery: Physicochemical Characterization, In Vitro Aerosol Dispersion, and Cellular Studies." Pharmaceutics 13, no. 1 (December 25, 2020): 26. http://dx.doi.org/10.3390/pharmaceutics13010026.

Full text
Abstract:
The purpose of this study was to formulate Lactomorphin (MMP2200) in its pure state as spray-dried(SD) powders, and with the excipient Trehalose as co-spray-dried(co-SD) powders; for intranasal and deep lung administration with Dry Powder Inhalers (DPI). Lactomorphin is a glycopeptide which was developed for the control of moderate to severe pain. Particles were rationally designed and produced by advanced spray drying particle engineering in a closed mode from a dilute organic solution. Comprehensive physicochemical characterization using different analytical techniques was carried out to analyze the particle size, particle morphology, particle surface morphology, solid-state transitions, crystallinity/non-crystallinity, and residual water content. The particle chemical composition was confirmed using attenuated total reflectance-Fourier-transform infrared (ATR-FTIR), and Confocal Raman Microscopy (CRM) confirmed the particles’ chemical homogeneity. The solubility and Partition coefficient (LogP) of Lactomorphin were determined by the analytical and computational methodology and revealed the hydrophilicity of Lactomorphin. A thermal degradation study was performed by exposing samples of solid-state Lactomorphin to a high temperature (62 °C) combined with zero relative humidity (RH) and to a high temperature (62 °C) combined with a high RH (75%) to evaluate the stability of Lactomorphin under these two different conditions. The solid-state processed particles exhibited excellent aerosol dispersion performance with an FDA-approved human DPI device to reach lower airways. The cell viability resazurin assay showed that Lactomorphin is safe up to 1000 μg/mL on nasal epithelium cells, lung cells, endothelial, and astrocyte brain cells.
APA, Harvard, Vancouver, ISO, and other styles
8

Srinivasan, Ganga, and Advait Shetty. "ADVANCEMENTS IN DRY POWDER INHALER." Asian Journal of Pharmaceutical and Clinical Research 10, no. 2 (February 1, 2017): 8. http://dx.doi.org/10.22159/ajpcr.2017.v10i2.14282.

Full text
Abstract:
The dry powder inhaler (DPI) has become widely known as a very attractive platform for drug delivery. DPIs are being used for the treatment of asthma and chronic obstructive pulmonary disease by many patients. There are over 20 devices presently in the DPI market. DPIs are preferred over nebulizers and pressurized metered dose inhalers. However, some of the challenges of DPI are dependence on inspiratory flow (unsuitable for young children, elderly people), systemic absorption due to deposition of drug in deep lung (unsuitable for local diseases treatment), and increase in upper airway deposition of a large fraction of coarse particles. Hence, there is a need to address these unmet issues. The interpatient variation can be minimized by developing devices independent of patient’s inspiratory flow rate or active based powder mechanism. This article reviews DPI devices currently available, advantages of newly developed devices, and formulation technologies. The platform technologies are developed to improve aerosolization and dispersion from the device and decrease the patient related factors. The DPI delivery system has been expanded to treatment of non-respiratory diseases such as migraine and diabetes. The development of innovative DPI device and formulation technologies for delivering therapeutic proteins such as insulin has been accelerated to overcome the problems associated with conventional insulin therapy.Keywords: Dry powder inhaler, Inspiratory flow rate, Insulin, Platform technologies.
APA, Harvard, Vancouver, ISO, and other styles
9

Chrystyn, H., and C. Niederlaender. "The Genuair® inhaler: a novel, multidose dry powder inhaler." International Journal of Clinical Practice 66, no. 3 (February 16, 2012): 309–17. http://dx.doi.org/10.1111/j.1742-1241.2011.02832.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Lavorini, Federico, and Giovanni A. Fontana. "Inhaler technique and patient's preference for dry powder inhaler devices." Expert Opinion on Drug Delivery 11, no. 1 (October 5, 2013): 1–3. http://dx.doi.org/10.1517/17425247.2014.846907.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Nasal dry powder inhaler"

1

Azimi, Mandana. "EVALUATION OF THE REGIONAL DRUG DEPOSITION OF NASAL DELIVERY DEVICES USING IN VITRO REALISTIC NASAL MODELS." VCU Scholars Compass, 2017. http://scholarscompass.vcu.edu/etd/4780.

Full text
Abstract:
The overall objectives of this research project were i) to develop and evaluate methods of characterizing nasal spray products using realistic nasal airway models as more clinically relevant in vitro tools and ii) to develop and evaluate a novel high-efficiency antibiotic nanoparticle dry powder formulation and delivery device. Two physically realistic nasal airway models were used to assess the effects of patient-use experimental conditions, nasal airway geometry and formulation / device properties on the delivery efficiency of nasal spray products. There was a large variability in drug delivery to the middle passages ranging from 17 – 57 % and 47 – 77 % with respect to patient use conditions for the two nasal airway geometries. The patient use variables of nasal spray position, head angle and nasal inhalation timing with respect to spray actuation were found to be significant in determining nasal valve penetration and middle passage deposition of Nasonex®. The developed test methods were able to reproducibly generate similar nasal deposition profiles for nasal spray products with similar plume and droplet characteristics. Differences in spray plume geometry (smaller plume diameter resulted in higher middle passage drug delivery) were observed to have more influence on regional nasal drug deposition than changes to droplet size for mometasone furoate formulations in the realistic airway models. Ciprofloxacin nanoparticles with a mean (SD) volume diameter of 120 (10) nm suitable for penetration through mucus and biofilm layers were prepared using sonocrystallization technique. These ciprofloxacin nanoparticles were then spray dried in a PVP K30 matrix to form nanocomposite particles with a mean (SD) volume diameter of 5.6 (0.1) µm. High efficiency targeted delivery of the nanocomposite nasal powder formulation was achieved using a modified low flow VCU DPI in combination with a novel breathing maneuver; delivering 73 % of the delivered dose to the middle passages. A modified version of the nasal airway model accommodating Transwell® inserts and a Calu-3 monolayer was developed to allow realistic deposition and evaluation of the nasal powder. The nanocomposite formulation was observed to demonstrate improved dissolution and transepithelial transport (flux = 725 ng/h/cm2) compared to unprocessed ciprofloxacin powder (flux = 321 ng/h/cm2).
APA, Harvard, Vancouver, ISO, and other styles
2

Stevens, Nia Eleri. "Multiphase modelling methods for dry powder inhaler flow." Thesis, Imperial College London, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.429946.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Tuley, Robert James. "Modelling dry powder inhaler operation with the discrete element method." Thesis, Imperial College London, 2008. http://hdl.handle.net/10044/1/7561.

Full text
Abstract:
Dry powder inhalers (DPI) are a common asthma treatment. Despite the number of commercial devices available, little is known about their internal operation: the process of fluidising a powder dose into an inhalation airflow. This PhD aims to investigate this process, and demonstrate that it can be modelled computationally. . Experimental work is described to record high speed video of the dose fluidisation from simplified DPls. Typical DPI powders such as lactose are tested, along with cohesionless glass spheres and aluminium flakes. Two distinct dose fluidisation mechanisms are identified, labelled 'fracture' and 'erosion'. Lactose exhibits a fracture mechanism -- large agglomerates are produced as the powder bed cracks along lines of weakness. Glass or aluminium particles exhibit an erosion mechanism: powder is entrained into the flow as individual particles from the bed surface. The recorded video is quantitatively analysed to determine fluidisation timescales and pressures. Shear cell test results show that predicting the mechanism of fluidisation is not possible using averaged bulk powder properties. This suggests any DPI model must include the fundamental particle interactions. The discrete element method (OEM) is introduced as a computational technique capable of predicting DPI behaviour from individual particle properties. The numerical accuracy of the method is assessed, showing that time integration is limited to a maximum of 2nd order accuracy due to discontinuities in particle contact forces. A sensitivity analysis shows inter-particle cohesion is the dominant factor affecting OEM predictions. OEM is used to create a simple model of the dose fluidisation that occurs within a DPI. The results are compared with real powder behaviour. OEM is shown to capture the realistic fluidisation of both lactose and glass powder doses. It is concluded that OEM is a promising technique to predict DPI behaviour, although further work is required to quantify inter--particle cohesive parameters
APA, Harvard, Vancouver, ISO, and other styles
4

Kopsch, Thomas. "Computational modelling and optimization of dry powder inhalers." Thesis, University of Cambridge, 2018. https://www.repository.cam.ac.uk/handle/1810/275902.

Full text
Abstract:
Dry powder inhalers (DPIs) are a common therapeutic modality for lung diseases such as asthma, but they are also used to treat systemic diseases such as diabetes. Advantages of DPIs include their portable design and low manufacturing costs. Another advantage of DPIs is their breath activation, which makes them popular among patients. In a passive DPI drug is only released when the patient inhales. When the patient inhales, air flows through the device. The flow of air entrains a dry powder formulation inside the device and carries it to the lung. Currently, no DPI exists which can deliver drug independent of the patient to the desired target site in the lung. This is because drug release depends on the patient’s inhalation manoeuvre. To maximize the effect of the treatment it is necessary to optimize DPIs to achieve drug delivery that (A) is independent of the inhalation manoeuvre and (B) is targeted to the correct site in the lung. Therefore, this thesis aims to apply numerical and experimental methods to optimize DPIs systematically. First, two clinically justifiable cost functions have been developed corresponding to the DPI design objectives (A) and (B). An Eulerian-Eulerian (EE) computational fluid dynamics (CFD) approach has then been used to optimize a DPI entrainment geometry. Three different optimized entrainment geometries have been found corresponding to three different therapeutic applications. Second, the CFD approach has been validated experimentally. This is the first experimental study to validate an EE CFD approach for DPI modelling. Third, a personalized medicine approach to DPI design has been proposed. The development of this approach makes it possible to achieve the design objectives for patients with highly different lung functions. Finally, an adaptive DPI with a variable bypass element has been developed. This DPI achieves design objectives (A) and (B) for patients with highly different lung functions with a single device. In contrast to the personalized medicine approach, there is no need to select the optimal amount of bypass, since the device adapts automatically.
APA, Harvard, Vancouver, ISO, and other styles
5

Danby, Matthew. "Towards the prediction of agglomerate behaviour in dry powder inhaler devices." Thesis, University of Southampton, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.536333.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Harris, Haggis. "Rapid preformulation screening of drug candidates for dry powder inhaler preparation." Thesis, University of Bath, 2008. https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.512332.

Full text
Abstract:
Candidate active pharmaceutical ingredients (APIs) are routinely tested to determine such parameters as physical stability, chemical stability, and bioavailability. Preformulation analysis of APIs does not currently attemept to determine whether they will perform to an acceptable level once they have been formulated. In practice, the APIs are subjected to extensive in vitro testing of their performance in a formulation, combined with optimisation of the formulation. This formulation testing is both time-consuming and expensive. In the field of pulmonary drug delivery from dry powder inhalers (DPIs), the API has to be aerosolized effectively in order to penetrate the lunfs and reach its deposition target. In a conventional ternary DPI fromulation, the API is combined with carrier lactose and fine lactose particles. The inter-particle forces between these three components and the bulk properties of the formulation determine the structure of the formulation and the aerolization performance of the API. In this study, physicochemical properties of salbutamol base and several of its salts were investigated both quantitatively and qualitatively. The in vitro deposition characteristics of the formulated APIs were also determined. The relationship between these parameters and the deposition was analysed to establish if a rapid preformulation screening technique could be applied to the APIs with respect to predicting the deposition performance of the formulated API. A clear relationship between the deposition of the unformulated API and the formulated API was observed that could be exploited as a screening technique.
APA, Harvard, Vancouver, ISO, and other styles
7

Lagercrantz, Forss Louise. "Adhesive mixtures for dry powder inhalation." Thesis, Uppsala universitet, Institutionen för farmaceutisk biovetenskap, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-447786.

Full text
Abstract:
When it comes to dry powder inhalation (DPI), adhesive mixtures are the most widely used formulation type. Various techniques have been developed to generate inhaled drug particles and improve the delivery efficiency of DPI formulations. For dry powder inhaler formulations (DPIs), micronized drug powders are usually mixed with lactose carriers to improve powder handling during manufacturing and powder aerosol delivery during patient use. The performance of DPI systems is strongly dependent on several formulation factors, the construction of the delivery device and the inhalation technique. There is a growing interest in DPI in new medical areas such as vaccines and antibiotics which requires further development and challenges to ensure physical and aerosolization stability of DPI.  This project aims to discuss the development of inhalation therapy, the challenges during formulation processes, the mixing process and the use of excipients in pulmonary drug delivery in DPIs. Further, the project is covered by experiments based on the literature overview and performed at the Department of Pharmaceutical Biosciences at Uppsala University. Bulk density was measured on three series of adhesive mixtures with increasing amounts of fine particles. In two series, small amounts of Magnesium Stearate, 0,1% and 0,01% were added.
APA, Harvard, Vancouver, ISO, and other styles
8

Robertson, Debra Louise Norton. "Effect of carrier shape and texture on drug availability of aerosolised particles." Thesis, University of Bath, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.389946.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Begat, Philippe Michel. "Quantification and control of cohesive and adhesive forces in dry powder inhaler formulations." Thesis, University of Bath, 2004. https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.415769.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Huang, Wenhua. "Investigation of semipermeable coated tablet and liposomal dry powder inhaler formulation of salbutamol sulfate." HKBU Institutional Repository, 2010. http://repository.hkbu.edu.hk/etd_ra/1159.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Nasal dry powder inhaler"

1

Dhand, Rajiv, and Michael McCormack. Bronchodilators in critical illness. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0033.

Full text
Abstract:
Inhaled beta-agonists and anticholinergic agents, as well as systemically administered methylxanthines, are frequently employed to achieve bronchodilation in critically-ill patients. Inhaled agents are given by pressurized metered dose inhaler (pMDI), nebulizer, or dry powder inhaler. In ventilator-supported patients, aerosolized agents are generally only administered by pMDI or nebulizer. The ventilator circuit, artificial airway, and circuit humidity complicate the delivery of aerosolized agents, and there is a wide variability in drug delivery efficiency with various bench models of mechanical ventilation. Aerosolized drug by pMDI is affected by the use of spacer devices, synchronization of pMDI actuation and ventilator breath delivery, and appropriate priming of the pMDI device. The efficiency of aerosolized drug delivery by jet nebulization is also affected by device placement in the circuit, as well as by a number of other factors. Several investigators have demonstrated comparable efficiency of aerosol delivery with mechanically-ventilated and ambulatory patients when careful attention is given to the technique of administration. Appropriate administration of aerosolized bronchodilators in patients receiving invasive or non-invasive positive pressure ventilation produces significant therapeutic effects.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Nasal dry powder inhaler"

1

Hickey, Anthony J. "Fundamentals of Dry Powder Inhaler Technology." In Particles and Nanoparticles in Pharmaceutical Products, 213–32. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-94174-5_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hickey, Anthony J., Herman Staats, Chad J. Roy, Kenneth G. Powell, Vince Sullivan, Ginger Rothrock, and Christie M. Sayes. "Nasal Dry Powder Vaccine Delivery Technology." In Molecular Vaccines, 717–26. Cham: Springer International Publishing, 2013. http://dx.doi.org/10.1007/978-3-319-00978-0_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Mei Jin Tan, Bernice, Celine Valeria Liew, Lai Wah Chan, and Paul Wan Sia Heng. "Particle Surface Roughness - Its Characterisation and Impact on Dry Powder Inhaler Performance." In Pulmonary Drug Delivery, 199–222. Chichester, UK: John Wiley & Sons, Ltd, 2015. http://dx.doi.org/10.1002/9781118799536.ch9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Milenkovic, Jovana, Alexandros H. Alexopoulos, and Costas Kiparissides. "Airflow and Particle Deposition in a Dry Powder Inhaler: An Integrated CFD Approach." In Advances in Intelligent Systems and Computing, 127–40. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-03581-9_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Reis, A. M., H. M. Cabral Marques, and I. W. Kellaway. "A Preliminary Study of a ß-Cyclodextrin/Salbutamol Complex for Possible Use in a Dry Powder Inhaler." In Proceedings of the Ninth International Symposium on Cyclodextrins, 203–6. Dordrecht: Springer Netherlands, 1999. http://dx.doi.org/10.1007/978-94-011-4681-4_47.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Dorosz, Agata, Paula Martínez Cánovas, and Arkadiusz Moskal. "Cascade Impactor Study of Aerosolization Process During Passive Dry Powder Inhaler Performance Under Unsteady Versus Steady Flow Conditions." In Practical Aspects of Chemical Engineering, 47–57. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-39867-5_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Yurdasiper, Aysu, Mesut Arici, Erkan Azizoğlu, and Mine Ozyazici. "Inhaler Systems: Dry Powder." In Encyclopedia of Biomedical Polymers and Polymeric Biomaterials, 4063–74. Taylor & Francis, 2016. http://dx.doi.org/10.1081/e-ebpp-120050077.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hamishehkar, Hamed, Yahya Rahimpour, and Yousef Javadzadeh. "The Role of Carrier in Dry Powder Inhaler." In Recent Advances in Novel Drug Carrier Systems. InTech, 2012. http://dx.doi.org/10.5772/51209.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Chapman, Stephen J., Grace V. Robinson, Rahul Shrimanker, Chris D. Turnbull, and John M. Wrightson. "Inhalers and nebulizers." In Oxford Handbook of Respiratory Medicine, edited by Stephen J. Chapman, Grace V. Robinson, Rahul Shrimanker, Chris D. Turnbull, and John M. Wrightson, 747–54. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780198837114.003.0054.

Full text
Abstract:
There are many different inhaler devices that deliver drugs directly to the airways, but essentially two basic types MDIs and dry powder inhalers (DPIs). New devices are being introduced all the time, with one, two, or three drugs delivered simultaneously.
APA, Harvard, Vancouver, ISO, and other styles
10

Alexopoulos, A. H., J. Milenkovic, and C. Kiparissides. "An Integrated Computational Model of Powder Release, Dispersion, Breakage, and Deposition in a Dry Powder Inhaler." In Computer Aided Chemical Engineering, 139–44. Elsevier, 2013. http://dx.doi.org/10.1016/b978-0-444-63234-0.50024-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Nasal dry powder inhaler"

1

Kotteda, V. M. Krushnarao, Antara Badhan, and Vinod Kumar. "Parametric Optimization of a Dry Powder Inhaler." In ASME 2020 Fluids Engineering Division Summer Meeting collocated with the ASME 2020 Heat Transfer Summer Conference and the ASME 2020 18th International Conference on Nanochannels, Microchannels, and Minichannels. American Society of Mechanical Engineers, 2020. http://dx.doi.org/10.1115/fedsm2020-20391.

Full text
Abstract:
Abstract In the present study, particles in cell method, a Eulerian-Lagrangian approach is used to simulate the flow in an inhaler. The number of uncertain parameters, including properties of particles, fluidizing agents’ properties, initial/boundary conditions, and numerical parameters related to PIC simulations, is fourteen. The residence time of 280 PIC simulations for different values of the uncertain parameters is used to test/train a data-driven framework. The values of the uncertain parameters are generated via the Latin Hypercube Sampling method and a normal distribution. The trained algorithm is used to predict the residence time for various unknown parameters. This framework is used to carry out the sensitivity analysis to find the most influential settings on the residence time of the particles in the inhaler. The optimum parameters of the influential parameters for a given residence time is calculated via the data-driven framework.
APA, Harvard, Vancouver, ISO, and other styles
2

Badhan, Antara, V. M. Krushnarao Kotteda, and Vinod Kumar. "CFD DEM Analysis of a Dry Powder Inhaler." In ASME-JSME-KSME 2019 8th Joint Fluids Engineering Conference. American Society of Mechanical Engineers, 2019. http://dx.doi.org/10.1115/ajkfluids2019-4771.

Full text
Abstract:
Abstract Dry powder inhalers (DPIs), used as a means for pulmonary drug delivery, typically contain a combination of active pharmaceutical ingredient (API) and significantly larger carrier particles. The micro-sized drug particles — which have a strong propensity to aggregate and poor aerosolization performance — mixed with significantly large carrier particles that are unable to penetrate the mouth-throat region to deagglomerate and entrain the smaller API particles in the inhaled airflow. The performance of a DPI, therefore, depends on entrainment the carrier-API combination particles and the time and thoroughness of the deagglomeration of the individual API particles from the carrier particles. Since DPI particle transport is significantly affected by particle-particle interactions, very different particles sizes and shapes, various forces including electrostatic and van der Waals forces, they present significant challenges to Computational Fluid Dynamics (CFD) modelers to model regional lung deposition from a DPI. In the current work, we present a novel high fidelity CFD discrete element modeling (CFD-DEM) and sensitivity analysis framework for predicting the transport of DPI carrier and API particles. The work integrates exascale capable CFD-DEM and sensitivity analysis capabilities by leveraging the Department of Energy (DOE) laboratories libraries: Multiphase Flow Interface Flow Exchange (MFiX) for CFD-DEM, and Trilinos for leading-edge portable/scalable linear algebra. We carried out a sensitivity analysis of various formulation properties and their effects on particle size distribution with Dakota, an open source software designed to exploit High-Performance Computing (HPC) capabilities of a massively parallel supercomputer. We developed wrappers to exchange information among these state-of-the-art tools for DPI.
APA, Harvard, Vancouver, ISO, and other styles
3

Amin Moghadassi, Hedieh, Atefeh Fakharian, Alireza Eslaminejad, Masoumeh Mehdipour, and Saranaz Azari-Marhabi. "Oral manifestations in asthmatic patients using metered dose inhaler and dry powder inhaler." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa4005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Greguletz, R., B. Fyrnys, J. Goede, A. Haaije de Boer, and H. Frijlink. "A Novel Multidose Dry Powder Inhaler Demonstrates Consistent Aerodynamic Features." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a4578.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hadinoto, Kunn, Wean Sin Cheow, and Katherine Kho. "Beyond Spray Drying: New Dry Powder Inhaler Frmulation of Drug Nanoparticles." In 5th Asian Particle Technology Symposium. Singapore: Research Publishing Services, 2012. http://dx.doi.org/10.3850/978-981-07-2518-1_382.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Chrystyn, Henry, Dinesh Saralaya, Anil Shenoy, Sophie Toor, Andrew Scally, Enric Calderon, and Guilherme Safioti. "Inhalation parameters from an integrated electronic multidose dry powder inhaler (eMDPI)." In ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.pa681.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Greguletz, R., M. Arlt, S. Anke, J. Goede, A. Haaije de Boer, and H. Frijlink. "A Novel Multidose Dry Powder Inhaler for the Delivery of Various Types of Inhalation Powder." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a2461.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

"Airflow and Particle Deposition in a Dry Powder Inhaler - A CFD Simulation." In 2nd International Conference on Simulation and Modeling Methodologies, Technologies and Applications. SciTePress - Science and and Technology Publications, 2012. http://dx.doi.org/10.5220/0004058102500259.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Zhou, Qi (Tony), Zhenbo Tong, Patricia Tang, Runyu Yang, and Hak-Kim Chan. "CFD analysis of the aerosolization of carrier-based dry powder inhaler formulations." In POWDERS AND GRAINS 2013: Proceedings of the 7th International Conference on Micromechanics of Granular Media. AIP, 2013. http://dx.doi.org/10.1063/1.4812139.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Allan, R., C. Newcomb, K. Canham, R. Wallace, and J. Ward. "Usability and Robustness of the Wixela® Inhub® Dry Powder Inhaler." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2206.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Nasal dry powder inhaler' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography